series-b
Stage
About
GABA Therapeutics is a mid-stage biotechnology company developing GRX-917, a deuterated analog of an anxiety medication that aims to provide benzodiazepine-like efficacy with reduced addiction risk by increasing endogenous neurosteroids and inhibiting NLRP3 inflammation.
Explore GABA Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.